Akums Drugs and Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums Drugs and Pharmaceuticals Limited has filed annual disclosures under SEBI Regulation 31(4) for FY 2025-26 (ended 31.03.2026). Two promoter Managing Directors, Sanjeev Jain and Sandeep Jain, submitted separate but identical declarations confirming that neither they nor their persons acting in concert have created any encumbrance (pledge) on the company's shares during the financial year. The disclosure lists 32 entities in the promoter group, including family members, three trusts, and various group companies. This is a nil disclosure, meaning no pledge activity was undertaken by the promoter group.
Positive for shareholders as it confirms promoters have not pledged their shares as collateral, reducing the risk of forced selling pressure. This indicates financial stability among the promoter group and no immediate threat of share dilution from encumbrance-related actions.